Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211354
Status:
WITHDRAWN
Last Update Posted:
2009-02-04
First Post:
2005-09-13
Brief Title:
Treatment of Retinal Vein Occlusion RVO With Open-Label Anecortave Acetate 15mg
Sponsor:
Manhattan Eye Ear Throat Hospital
Organization:
Manhattan Eye Ear Throat Hospital
Study Overview
Official Title:
None
Status:
WITHDRAWN
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No subjects enrolled
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Retinal Vein Occlusion is a blockage of the blood vessels that drain out of the retina Complications of retinal vein occlusion which threaten vision include neovascularizationgrowth of new blood vesselsand macular edema accumulation of fluid leaking from abnormal blood vessels Currently the treatment of retinal vein occlusion is laser photocoagulation This treatment has found to have limited use in this type of conditionAnecortave Acetate is being considered as an attempt to control the growth of the abnormal blood vessels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None